Fosun Pharma
Fosun Pharma
Fosun Pharma is a pharmaceutical company.
Fosun Pharma, founded in May, 1995 and headquartered in Shanghai, is a pharmaceutical distribution, retail and medical service company. The founders are Chen Qiyu and Yao Fang. Listed on the HKEX on October 30, 2012, the company's major shareholders are Shanghai Fosun High Technology (Group) Co., Ltd., HKSCC Nominees Ltd and Hong Kong Securities Clearing Co., Ltd. Rivals that have direct and indirect competition with Fosun Pharma include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
Briefing Jan 07, 2021 04:13 PM
· Healthcare
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Briefing Dec 31, 2020 10:20 AM
· Healthcare
Sinopharm new coronavirus vaccine approved
In depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Briefing Dec 28, 2020 03:13 PM
· Healthcare
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Discretionary, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Consumer Discretionary, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Briefing Dec 23, 2020 11:21 AM
· Healthcare
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Briefing Dec 20, 2020 02:22 PM
· Healthcare
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Briefing Dec 16, 2020 02:27 PM
· Healthcare
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Briefing Nov 20, 2020 08:14 PM
· Healthcare
Pfizer submitted to FDA for authorization of emergency use of new crown vaccine
Briefing Nov 20, 2020 11:57 AM
· Healthcare
The new crown vaccine developed by academician Chen Wei and kangxinuo biology can be stable for a long time from 2 to 8 degrees
In depth
In depth
Briefing Nov 19, 2020 10:22 AM
· Healthcare
Geli pharmaceutical: asc40 (tvb-2640) China has completed phase II NASH patients
Briefing Nov 19, 2020 09:57 AM
· Healthcare
Heyuan biological has completed a new round of financing of 450 million yuan, and car-t products with independent intellectual property rights have entered clinical phase II
Briefing Nov 19, 2020 09:33 AM
· Healthcare
Baiji Shenzhou: midterm analysis of the global phase III clinical trial for the treatment of non-small cell lung cancer reached the main end point
Briefing Nov 17, 2020 08:04 PM
· Healthcare
Plan to raise $4 billion! Jingdong health runs IPO
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
- Tong Ren Tang: Any Hope for this Purveyor of Centuries-Old Chinese Medicines?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.